Converge Bio’s successful $25 million funding round marks a major milestone in the evolution of AI-driven drug discovery, reinforcing growing investor confidence in generative AI’s role within life sciences. Backed by Bessemer Venture Partners and senior executives from Meta, OpenAI, and Wiz, the company is rapidly scaling its platform to transform how pharmaceutical research is conducted moving faster, smarter, and with greater precision.
At the core of Converge Bio’s momentum is a generative AI platform already supporting around 40 active drug programs and trusted by 40+ pharma and biotech partners worldwide. The impact is tangible. From achieving fourfold increases in protein yield to enabling high-affinity antibody generation, the platform is delivering measurable breakthroughs that address long-standing inefficiencies in drug development. These results highlight how AI is no longer experimental in pharma it is becoming foundational.
CEO and co-founder Dov Gertz emphasises that drug development follows defined stages, from early discovery to manufacturing and clinical trials, and within each stage lie opportunities for AI-powered experimentation. Converge Bio’s technology is built to expand seamlessly across this entire lifecycle, helping researchers reduce timelines and bring therapies to patients faster.
As pressure mounts on the pharmaceutical industry to innovate efficiently, Converge Bio stands out as a company turning AI ambition into real-world outcomes, redefining what speed and scale look like in modern drug discovery.
